219 related articles for article (PubMed ID: 17993846)
1. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
2. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
3. Radiation doses to patient's relatives following radioiodine therapy.
Sulaiman BT; Clarke SE
Med J Malaysia; 1996 Mar; 51(1):131-3. PubMed ID: 10967992
[TBL] [Abstract][Full Text] [Related]
4. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
[No Abstract] [Full Text] [Related]
5. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
6. 131I effective half-life (Teff) for patients with thyroid cancer.
Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
[TBL] [Abstract][Full Text] [Related]
7. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
[TBL] [Abstract][Full Text] [Related]
8. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer.
Hernández-Jardines A; Molina B; del Castillo V; Papadakis M; Rivera T; Azorín J; Herrera LA; Yokoyama E; Frías S
Rev Invest Clin; 2010; 62(1):31-8. PubMed ID: 20415057
[TBL] [Abstract][Full Text] [Related]
9. Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models.
Willegaignon J; Guimarães MI; Stabin MG; Sapienza MT; Malvestiti LF; Marone MM; Sordi GM
Health Phys; 2007 Dec; 93(6):678-88. PubMed ID: 17993848
[TBL] [Abstract][Full Text] [Related]
10. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
Parthasarathy KL; Crawford ES
J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
[TBL] [Abstract][Full Text] [Related]
11. Radiation safety when a patient dies after therapy.
Bybel B; Blais M; Vandierendonck R; Driedger AA
J Nucl Med Technol; 1998 Sep; 26(3):206-7. PubMed ID: 9755443
[TBL] [Abstract][Full Text] [Related]
12. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
[TBL] [Abstract][Full Text] [Related]
13. Radiation safety considerations for post-iodine-131 thyroid cancer therapy.
Culver CM; Dworkin HJ
J Nucl Med; 1992 Jul; 33(7):1402-5. PubMed ID: 1613585
[TBL] [Abstract][Full Text] [Related]
14. A new proposal for monitoring patients in nuclear medicine.
Willegaignon J; Guimarães MI; Sapienza MT; Stabin MG; Malvestiti LF; Marone M; Sordi GM
Health Phys; 2006 Dec; 91(6):624-9. PubMed ID: 17099406
[TBL] [Abstract][Full Text] [Related]
15. Measurement of radiation exposure in relatives of thyroid cancer patients treated with (131)I.
Ramírez-Garzón YT; Ávila O; Medina LA; Gamboa-deBuen I; Rodríguez-Laguna A; Buenfil AE; Ruíz-Trejo C; Estrada E; Brandan ME
Health Phys; 2014 Nov; 107(5):410-6. PubMed ID: 25271931
[TBL] [Abstract][Full Text] [Related]
16. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I.
Siegel JA; Marcus CS; Stabin MG
Health Phys; 2007 Dec; 93(6):667-77. PubMed ID: 17993847
[TBL] [Abstract][Full Text] [Related]
17. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
18. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
19. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.
Willegaignon J; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Clin Nucl Med; 2011 Jun; 36(6):440-5. PubMed ID: 21552020
[TBL] [Abstract][Full Text] [Related]
20. Outpatient therapeutic 131I for thyroid cancer.
Panzegrau B; Gordon L; Goudy GH
J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
